Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.

Literature DB >> 26456776

Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.

Panagiotis I Georgianos¹, Pantelis A Sarafidis², Vassilios Liakopoulos¹, Elias V Balaskas¹, Pantelis E Zebekakis¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2015 PMID： 26456776 PMCID： PMC8031554 DOI： 10.1111/jch.12718

Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN： 1524-6175 Impact factor: 3.738

× No keyword cloud information.

24 in total

1. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Authors: Pantelis A Sarafidis; Rochelle Blacklock; Eleri Wood; Adam Rumjon; Shanique Simmonds; Jessica Fletcher-Rogers; Rachel Ariyanayagam; Aziza Al-Yassin; Claire Sharpe; Katie Vinen
Journal: Clin J Am Soc Nephrol Date: 2012-05-17 Impact factor: 8.237

2. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

Authors: Evan Gross; Marcos Rothstein; Susan Dombek; Henrikas Irmantas Juknis
Journal: Am J Kidney Dis Date: 2005-07 Impact factor: 8.860

3. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.

Authors: Michael Walsh; Braden Manns; Amit X Garg; Joe Bueti; Christian Rabbat; Andrew Smyth; Jessica Tyrwhitt; Jackie Bosch; Peggy Gao; P J Devereaux; Ron Wald
Journal: Clin J Am Soc Nephrol Date: 2015-07-02 Impact factor: 8.237

Review 4. The interplay between CKD, sudden cardiac death, and ventricular arrhythmias.

Authors: Patrick H Pun
Journal: Adv Chronic Kidney Dis Date: 2014-10-24 Impact factor: 3.620

5. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Authors: Bertram Pitt; Nathaniel Reichek; Roland Willenbrock; Faiez Zannad; Robert A Phillips; Barbara Roniker; Jay Kleiman; Scott Krause; Daniel Burns; Gordon H Williams
Journal: Circulation Date: 2003-09-29 Impact factor: 29.690

Review 6. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.

Authors: Nancy J Brown
Journal: Nat Rev Nephrol Date: 2013-06-18 Impact factor: 28.314

7. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients.

Authors: Panayota Flevari; Sofia Kalogeropoulou; Athina Drakou; Dionyssios Leftheriotis; Fotis Panou; John Lekakis; Demetrios Kremastinos; Demetrios V Vlahakos
Journal: J Hypertens Date: 2013-06 Impact factor: 4.844

8. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Authors: Yoshihiro Matsumoto; Yasuo Mori; Shinji Kageyama; Kazuo Arihara; Toshikazu Sugiyama; Hiromichi Ohmura; Toru Yakushigawa; Hatsumi Sugiyama; Yasushi Shimada; Youichi Nojima; Nobuo Shio
Journal: J Am Coll Cardiol Date: 2013-10-30 Impact factor: 24.094

Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.

1. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

2. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

3. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.

Review 4. The interplay between CKD, sudden cardiac death, and ventricular arrhythmias.

5. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Review 6. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.

7. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients.

8. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

9. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study.

10. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.

Review 1. Pharmacotherapy of Hypertension in Chronic Dialysis Patients.

Review 2. Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis.